Based only on the facts in our directory. The right pick still depends on the job you need done.
Lower starting price
Not comparable
Not comparable: Paige does not list a price
Free plan
Tie
Neither has one
Higher rating
Tempus AI
4.1 against 4.3
Same job?
Yes
Both are Healthcare AI tools
Side by side
Compared on
Paige
Tempus AI
Our rating
4.1
4.3Better
Starts at
Not listed
Not listed
Free plan
No
No
Category
Healthcare AI
Healthcare AI
Plans
See pricing
See pricing
Key features
Paige Alba AI co-pilot for digital pathology tissue-slide analysis
Cancer diagnosis, tissue subtyping, and molecular biomarker discovery support
Founded in 2017 by researchers from Memorial Sloan Kettering Cancer Center
Acquired by Tempus in August 2025, continuing under its own brand
Enterprise deployment with dedicated support for hospital and lab pathology teams
Machine learning applied to genomic and clinical data for precision treatment matching
One of the largest connected libraries of clinical and molecular data
Publicly traded on Nasdaq under the ticker TEM
Q1 2026 revenue of $348.1M, up 36.1% year over year
2026 revenue guidance raised to $1.59-$1.60 billion
Pros
Research pedigree from Memorial Sloan Kettering lends real clinical credibility
Tempus backing adds financial resources and precision-medicine data integration
Deep oncology pathology specialization outperforms general-purpose medical imaging AI
Publicly reported financials give unusual transparency into scale and growth
Massive, growing data library strengthens precision-matching over time
Strong, consistent revenue growth across both diagnostics and data segments
Cons
Enterprise-only pricing requires a sales conversation before evaluation
Now part of a larger company, a real change from its independent-startup years
Narrow pathology focus means it's not a fit for non-oncology diagnostic workflows
Pricing runs through insurance billing and enterprise agreements, not published rates
Built specifically for precision medicine and oncology, a narrower clinical scope
Best suited to institutions already positioned to act on genomic testing results
Company
Paige, founded 2017
Tempus AI, founded 2015
Prices come from each vendor's pricing page, last checked 20260716. Check the vendor before you buy.
FAQ
Questions people ask
Is Paige better than Tempus AI?
In our reviews Paige scores 4.1 and Tempus AI scores 4.3. The better pick depends on the job. Paige: Digital pathology AI co-pilot from Memorial Sloan Kettering researchers, acquired by Tempus in 2025. Tempus AI: Publicly traded on Nasdaq, guiding to $1.6 billion in 2026 revenue.
Tempus AI
Paige
